Coya TherapeuticsCOYA
COYA
About: Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Employees: 8
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
23% more funds holding
Funds holding: 26 [Q1] → 32 (+6) [Q2]
1.34% less ownership
Funds ownership: 27.87% [Q1] → 26.53% (-1.34%) [Q2]
15% less capital invested
Capital invested by funds: $30.2M [Q1] → $25.5M (-$4.66M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
115%
upside
Avg. target
$16.50
154%
upside
High target
$18
177%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 177%upside $18 | Buy Maintained | 25 Aug 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 177%upside $18 | Buy Reiterated | 25 Aug 2025 |
Chardan Capital Keay Nakae | 115%upside $14 | Buy Maintained | 13 Aug 2025 |
Lake Street Chad Messer | 146%upside $16 | Buy Initiated | 9 Jul 2025 |
Financial journalist opinion
Based on 3 articles about COYA published over the past 30 days
Neutral
PRNewsWire
23 hours ago
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON , Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration ("FDA" or the "Agency") has accepted its Investigational New Drug (IND) application for COYA 302. This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Negative
Zacks Investment Research
1 week ago
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
Coya Therapeutics, Inc. (COYA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.
Neutral
PRNewsWire
1 week ago
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
HOUSTON , Aug. 12, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended June 30, 2025. Recent Corporate Highlights Submitted to FDA on June 30, 2025, additional nonclinical data to support the start of the COYA 302 Phase 2 trial in patients with ALS Published results of scientific research linking inflammation and oxidative stress to the progression of Parkinson's Disease (PD).
Positive
Zacks Investment Research
1 month ago
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
1 month ago
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the publication of a new research study, partially funded by Coya. The study, led by Drs. Aaron Thome, a scientific advisor to Coya, and Stanley H. Appel, the chairperson of Coya's Scientific Advisory Board, explores the role of immu.
Neutral
Business Wire
1 month ago
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the management team will participate in the BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. For more information about the BTIG Virtual Biotechnology Conference, or to register and schedule a one-on-one meeting with management, please contact your BTIG representat.
Neutral
Business Wire
2 months ago
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: https://www.
Neutral
Business Wire
2 months ago
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”) today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin). Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related int.
Neutral
Business Wire
3 months ago
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event.
Neutral
Business Wire
3 months ago
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose (LD) IL-2 and CTLA4-Ig combination treatment in pa.
Charts implemented using Lightweight Charts™